Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist

Immunology and Cell Biology

Volumn 90, Issue 6, 2012, Pages 630-639

  Walker, Kyle M ^a   Rytelewski, Mateusz ^a   Mazzuca, Delfina M ^a   Meilleur, Shannon A ^a   Mannik, Lisa A ^a   Yue, David ^a   Brintnell, William C ^a   Welch, Ian ^a   Cairns, Ewa ^a   Haeryfar, S M Mansour ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

a Galactosylceramide; citrulline; invariant NKT cell; OCH; rheumatoid arthritis

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CITRULLINE; FIBRINOGEN; GLYCOLIPID OCH; GLYCOSPHINGOLIPID; HLA DR4 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL POLARITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PROTEIN MODIFICATION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SPLEEN CELL; TH1 CELL; TH2 CELL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CITRULLINE; FEMALE; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HLA-DR4 ANTIGEN; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, TRANSGENIC; NATURAL KILLER T-CELLS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84863728830     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.78     Document Type: Article

References (61)

1. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-1213.
2. Meyer JM, Evans TI, Small RE, Redford TW, Han J, Singh R et al. HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis. J Rheumatol 1999; 26: 1024-1034.
3. Van Venrooij WJ, Pruijn GJ. An important step towards completing the rheumatoid arthritis cycle. Arthritis Res Ther 2008; 10: 117.
4. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin. J Immunol 2001; 166: 4177-4184.
5. Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 2006; 65: 1013-1020.
6. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171: 538-541.
7. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
8. van der Helm-van Mil AH, Verpoort KN, le CS, Huizinga TW, de Vries RR, Toes RE. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007; 56: 425-432.
9. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2: 236-243.
10. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-2749.
11. van Gaalen FA, Linn-Rasker SP, Van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-715.
12. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004; 6: R303-R308.
13. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831-1835.
14. van Gaalen FA, van AJ, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004; 50: 2113-2121.
15. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 23: 877-900.
16. Wu L, Van KL. Natural killer T cells and autoimmune disease. Curr Mol Med 2009; 9: 4-14.
17. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9: 28-38.
18. Fowlkes BJ, Kruisbeek AM, Ton-That H, Weston MA, Coligan JE, Schwartz RH et al. A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature 1987; 329: 251-254.
19. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8-T cells in mice and humans. J Exp Med 1994; 180: 1097-1106.
20. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629.
21. Hong C, Park SH. Application of natural killer T cells in antitumor immunotherapy. Crit Rev Immunol 2007; 27: 511-525.
22. Haeryfar SM. Invariant natural killer T cells in immune surveillance and tumor immunotherapy: perspectives and potentials. Arch Iran Med 2008; 11: 186-195.
23. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008; 101: 277-348.
24. Veldt BJ, van der Vliet HJ, von Blomberg BM, vanVlierberghe H, Gerken G, Nishi N et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 2007; 47: 356-365.
25. Woltman AM, Ter Borg MJ, Binda RS, Sprengers D, von Blomberg BM, Scheper RJ et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled phase I/II trial. Antivir Ther 2009; 14: 809-818.
26. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 2003; 198: 1069-1076.
27. Haeryfar SM, Lan Z, Leon-Ponte M, Duffy KR, Ge W, Liu Wet al. Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH. Transplantation 2008; 86: 460-468.
28. Mizuno M, Masumura M, Tomi C, Chiba A, Oki S, Yamamura T et al. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 2004; 23: 293-300.
29. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413: 531-534.
30. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosinetruncated analog of alpha-galactosylceramide. Arthritis Rheum 2004; 50: 305-313.
31. Miellot-Gafsou A, Biton J, Bourgeois E, Herbelin A, Boissier MC, Bessis N. Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment. Immunology 2010; 130: 296-306.
32. Cope AP, Patel SD, Hall F, Congia M, Hubers HAJM, Verheijden GF et al. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum 1999; 42: 1497-1507.
33. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008; 205: 967-979.
34. Ito K, Bian HJ, Molina M, Han J, Magram J, Saar E et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996; 183: 2635-2644.
35. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anticitrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089-1093.
36. Hill JA, Al-Bishri J, Gladman DD, Cairns E, Bell DA. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 2115-2119.
37. La CA, Van KL, Fu DS. CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol 2006; 27: 322-327.
38. Ly D, Mi QS, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 2006; 177: 3695-3704.
39. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 2003; 198: 1631-1641.
40. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623-1626.
41. Parekh VV, Singh AK, Wilson MT, Olivares-Villagómez D, Bezbradica JS, Inazawa H et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha-and beta-anomeric glycolipids. J Immunol 2004; 173: 3693-3706.
42. Yue D, Brintnell W, Mannik LA, Christie DA, Haeryfar SMM, Madrenas J et al. CTLA4-Ig blocks the development and progression of citrullinated fibrinogen-induced arthritis in DR4 tg mice. Arthritis Rheum 2010; 62: 2941-2952.
43. van den Heuvel MJ, Garg N, Van KL, Haeryfar SM. NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol Med 2011; 17: 65-77.
44. Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 2008; 10: R105.
45. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S. The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum 2005; 52: 1941-1948.
46. Coppieters K, Van BK, Jacques P, Dewint P, Vervloet A, Vander Cruyssen B et al. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J Immunol 2007; 179: 2300-2309.
47. Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, Kim HS et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000; 119: 119-128.
48. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001; 7: 1057-1062.
49. Tabushi Y, Nakanishi T, Takeuchi T, Nakajima M, Ueda K, Kotani T et al. Detection of citrullinated proteins in synovial fluids derived from patients with rheumatoid arthritis by proteomics-based analysis. Ann Clin Biochem 2008; 45: 413-417.
50. Tilleman K, Van SK, Cantaert T, De KF, Elewaut D, Deforce D. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) 2008; 47: 597-604.
51. Kinloch A, Lundberg K, Wait R, Wegner N, Lim NH, Zendman AJ et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008; 58: 2287-2295.
52. Goeb V, Thomas-L'Otellier M, Daveau R et al. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther 2009; 11: R38.
53. Taneja V, David CS. Role of HLA class II genes in susceptibility/ resistance to inflammatory arthritis: studies with humanized mice. Immunol Rev 2010; 233: 62-78.
54. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P et al. CD1dmediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188: 1521-1528.
55. Yu KO, Im JS, Molano A, Illarionov PA, Forestier C, Fujiwara N et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 2005; 102: 3383-3388.
56. Forestier C, Takaki T, Molano A, Im JS, Baine I, Jerud ES et al. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J Immunol 2007; 178: 1415-1425.
57. Kim HY, Kim HJ, Min HS, Kim S, Park WS, Park SH et al. NKT cells promote antibodyinduced joint inflammation by suppressing transforming growth factor beta1 production. J Exp Med 2005; 201: 41-47.
58. Linsen L, Thewissen M, Baeten K, Somers V, Geusens P, Raus J et al. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R493-R502.
59. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000; 192: 741-754.
60. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000; 191: 1895-1903.
61. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006; 443: 998-1002.